Adjuvant treatment with mRNA-4157 plus pembrolizumab led to a 65% reduction in the risk of distant metastasis or death compared with pembrolizumab alone, among patients with resected melanoma at high risk of recurrence, according to findings from the phase 2 KEYNOTE-942 trial (NCT03897881) that were presented at the 2023 ASCO Annual Meeting.
Clinical Trials
Melanoma-Specific Survival Longer With Nivolumab Plus Relatlimab Combined Treatment
Nivolumab plus relatlimab showed a clear benefit in progression-free survival, overall survival and objective response rate.
New Treatment Strategies and Therapies in Pediatric Dermatologic Conditions
Treating rare or even common dermatologic conditions in pediatric patients requires expert knowledge as well as compassion. Attendees at the 2023 Fall Clinical Dermatology Conference for PAs and NPs were eager to attend Adelaide Hebert’s, MD, session, “What is New in Pediatric Dermatology.”
PRT811 Shows Preliminary Efficacy, Consistent Safety in Advanced Glioma and Uveal Melanoma
PRT811, a protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor, has exhibited clinical activity and an acceptable safety profile in patients with IDH-positive recurrent, high-grade glioma and splicing mutation (SPLC)-positive uveal melanoma treated in the dose-expansion stage of a phase 1 study (NCT04089449), consistent with findings from the dose-escalation stage of the trial.